Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc > While yur still bent over....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(228)
•••
Comment by Dibah42on Apr 24, 2016 3:16pm
353 Views
Post# 24804124

RE:While yur still bent over....

RE:While yur still bent over....
I don't evaluate an early stage biotech on the banal metrics of last year's revenues, ebidat, loss, etc.. but for what it has in the pipeline and what it might bring to the market in the near future.  If you follow your own logic, you should never have bought into CUR either.
But, hey,  I am probably wasting my time on you.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities